Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.

Scientific reports - 25 Jun 2021

Wang Siao-Yi, Moore Tamson V, Dalheim Annika V, Scurti Gina M, Nishimura Michael I

Abstract excerpt

Adoptive T cell therapy with T cell receptor (TCR)-modified T cells has shown promise in treating metastatic melanoma and other malignancies. However, studies are needed to improve the efficacy and durability of responses of TCR-modified T cells. Standard protocols for generating TCR-modified T cells involve activating T cells through CD3 stimulation to allow for the efficient transfer of tumor-reactive receptors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell- and Tissue-Based Therapy
Share to Immunologic Memory

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-7

Share to Lymphocyte Activation

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Receptors, Antigen, T-Cell

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 34172810
DOI: 10.1038/s41598-021-92808-6
PMCID: PMC8233420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.PMID 34172810Read ↗

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenSemantic proximity Read ↗

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity Read ↗

Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.Semantic proximity Read ↗

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.Semantic proximity Read ↗

Adoptive immunotherapy for cancer: the next generation of gene‐engineered immune cellsSemantic proximity Read ↗

IL-7R licenses a population of epigenetically poised memory CD8 + T cells with superior antitumor efficacy that are critical for melanoma memorySemantic proximity Read ↗

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy StudiesSemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.Semantic proximity Read ↗

Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene TransferSemantic proximity Read ↗

Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanomaSemantic proximity Read ↗

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.